Valentín Cabañas

Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study

Aina Oliver‐Caldés, Verónica González‐Calle, Valentín Cabañas et al. · The Lancet Oncology · 2023 · 87 citations · Full text

Medicine, Hematology, Immunology +17

Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma

Laura Rosiñol, Albert Oriol, Rafael Ríos et al. · Blood · 2023 · 57 citations · Full text

Medicine, Hematology, Oncology +14

Imaging and bone marrow assessments improve minimal residual disease prediction in multiple myeloma

Rafael Alonso, María‐Teresa Cedena, Adolfo Gómez‐Grande et al. · American Journal of Hematology · 2019 · 53 citations · Full text

Medicine, Hematology, Oncology +17

Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma

Rosalinda Termini, David Žihala, Evangelos Terpos et al. · Clinical Cancer Research · 2022 · 52 citations · Full text

Medicine, Hematology, Oncology +17

Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma

Noemí Puig, María-Teresa Contreras, Cristina Agulló et al. · Blood Advances · 2022 · 50 citations · Full text

Life Sciences, Hematology, Immunology +17